About Incyte
Incyte is a company based in Wilmington (United States) founded in 1991. It operates as a Professional Services. The company has 2,620 employees as of December 31, 2024. Incyte has completed 4 acquisitions, including Escient Pharmaceuticals, Proteome and Vega Therapeutics. Incyte offers products and services including Oncology Solutions and Dermatology Solutions. Incyte operates in a competitive market with competitors including Moderna, BeiGene, MorphoSys, LEO Pharma and Annexon, among others.
- Headquarter Wilmington, United States
- Employees 2620 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Incyte Corporation
-
Annual Revenue
$4.24 B (USD)14.76as on Dec 31, 2024
-
Net Profit
$32.62 M (USD)-94.54as on Dec 31, 2024
-
EBITDA
$169.39 M (USD)-76.94as on Dec 31, 2024
-
Latest Funding Round
$750 M (USD), Post-IPO
Nov 14, 2013
-
Investors
Not available
-
Employee Count
2620
as on Dec 31, 2024
-
Investments & Acquisitions
Escient Pharmaceuticals
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Incyte
Incyte is a publicly listed company on the NASDAQ with ticker symbol INCY in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Incyte
Incyte offers a comprehensive portfolio of products and services, including Oncology Solutions and Dermatology Solutions.
Innovative treatments for cancer are developed and provided.
Therapies for skin conditions are researched and offered.
People of Incyte
Unlock access to complete
Unlock access to complete
Leadership Team
248 people
Software Development Team
124 people
Product Management Team
57 people
Senior Team
48 people
Dermatology Team
45 people
Operations Team
44 people
Legal and Compliance
33 people
Finance and Accounting
28 people
Unlock access to complete
Funding Insights of Incyte
Investments & Acquisitions by Incyte
Incyte has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Escient Pharmaceuticals, Proteome and Vega Therapeutics.
Investment portfolio details for Incyte
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Novel antibody therapeutics for vitiligo treatment are developed.
|
Locked | Locked | 2019 | Locked | |
|
Solutions for rare blood disorders are provided by Vega Therapeutics.
|
Locked | Locked | 2018 | Locked | |
|
Small molecule therapeutics for inflammatory diseases are developed.
|
Locked | Locked | 2017 | Locked |
Complete acquisition details for Incyte
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Incyte
Detailed financials for Incyte
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Incyte Comparisons
Peer comparison for Incyte
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Incyte
Incyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, MorphoSys, LEO Pharma and Annexon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating dermatology diseases
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
Detailed competitors of Incyte
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Incyte
Complete news archive for Incyte
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Incyte
Incyte was founded in 1991 and raised its 1st funding round 22 years after it was founded.
Incyte is headquartered in Wilmington, United States. It is registered at Wilmington, Delaware, United States.
Herve Hoppenot is the current CEO of Incyte.
As of Dec 31, 2024, the latest employee count at Incyte is 2,620.
Annual revenue of Incyte is $4.24B as on Dec 31, 2024.
Incyte is engaged in the development of biopharmaceutical solutions targeting unmet medical needs. The company operates in the healthcare sector, with a focus on oncology and dermatology. Innovative treatments and therapies are developed to address complex health challenges. Partnerships and scientific excellence are emphasized to drive patient-centered solutions globally.
Incyte's top competitors include Moderna, BeiGene and Regeneron Pharmaceuticals.
Incyte offers Oncology Solutions and Dermatology Solutions.
Yes, Incyte is publicly traded on NASDAQ under the ticker symbol INCY.
Incyte has made 4 acquisitions, including Escient Pharmaceuticals, Proteome, and Vega Therapeutics.
The ticker symbol of Incyte is INCY on NASDAQ.